Clinical significance and association of RUNX3 hypermethylation frequency with colorectal cancer: A meta-analysis

OncoTargets and Therapy

Volumn 7, Issue , 2014, Pages 1237-1245

  Mu, Wei Ping ^a   Wang, Jian ^a   Niu, Qiong ^a   Shi, Ning ^a   Lian, Hai Feng ^a  

^a BINZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Hazard ratio; Methylation; Microsatellite instability; Odds ratio; Tumor suppressor gene

Indexed keywords

TRANSCRIPTION FACTOR RUNX3;

ARTICLE; CANCER GROWTH; CANCER STAGING; CARCINOGENESIS; COLORECTAL CANCER; DATA ANALYSIS; DATA EXTRACTION; EARLY CANCER; GENE EXPRESSION; GENE INACTIVATION; HAZARD RATIO; HUMAN; INTESTINE MUCOSA; MEDLINE; META ANALYSIS (TOPIC); MICROSATELLITE INSTABILITY; PROTEIN EXPRESSION; PROTEIN METHYLATION; PUBLICATION; QUANTITATIVE ANALYSIS; RISK ASSESSMENT; SURVIVAL RATE; SYSTEMATIC REVIEW;

EID: 84904325468     PISSN: None     EISSN: 11786930     Source Type: Journal    
DOI: 10.2147/OTT.S62103     Document Type: Article

References (57)

1. Jemal A, Center MM, DeSantis C, Ward EM. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev. 2010;19(8):1893-1907.
2. Dai Z, Zheng RS, Zou XN, et al. [Analysis and prediction of colorectal cancer incidence trend in China.] Zhonghua Yu Fang Yi Xue Za Zhi. 2012;46(7):598-603. Chinese.
3. International Agency for Research on Cancer (IARC). Globocan 2008: Colorectal Cancer Fact Sheet 2008. Lyon: IARC; 2008. Available from: http://globocaniarcfr/factsheets/cancers/colorectalasp.
4. Weitz J, Koch M, Debus J, Höhler T, Galle PR, Büchler MW. Colorectal cancer. Lancet. 2005;365(9454):153-165.
5. McKeown E, Nelson DW, Johnson EK, et al. Current Approaches and Challenges for Monitoring Treatment Response in Colon and Rectal Cancer. J Cancer. 2014;5(1):31-43.
6. Solier S, Zhang Y W, Ballestrero A, Pommier Y, Zoppoli G. DNA damage response pathways and cell cycle checkpoints in colorectal cancer: current concepts and future perspectives for targeted treatment. Curr Cancer Drug Targets. 2012;12(4):356-371.
7. Duthie SJ. Folate and cancer: how DNA damage, repair and methylation impact on colon carcinogenesis. J Inherit Metab Dis. 2011;34(1):101-109.
8. Ozaki T, Nakagawara A, Nagase H. RUNX Family Participates in the Regulation of p53-Dependent DNA Damage Response. Int J Genomics. 2013;2013:271347.
9. Ito Y. RUNX genes in development and cancer: regulation of viral gene expression and the discovery of RUNX family genes. Adv Cancer Res. 2008;99:33-76.
10. Blyth K, Cameron ER, Neil JC. The RUNX genes: gain or loss of function in cancer. Nat Rev Cancer. 2005;5(5):376-387.
11. Subramaniam MM, Chan J Y, Yeoh KG, Quek T, Ito K, Salto-Tellez M. Molecular pathology of RUNX3 in human carcinogenesis. Biochim Biophys Acta. 2009;1796(2):315-331.
12. Lund AH, van Lohuizen M. RUNX: a trilogy of cancer genes. Cancer Cell. 2002;1(3):213-215.
13. Levanon D, Negreanu V, Bernstein Y, Bar-Am I, Avivi L, Groner Y. AML1, AML2, and AML3, the human members of the runt domain gene-family: cDNA structure, expression, and chromosomal localization. Genomics. 1994;23(2):425-432.
14. Shiraha H, Nishina S, Yamamoto K. Loss of runt-related transcription factor 3 causes development and progression of hepatocellular carcinoma. J Cell Biochem. 2011;112(3):745-749.
15. Li QL, Ito K, Sakakura C, et al. Causal relationship between the loss of RUNX3 expression and gastric cancer. Cell. 2002;109(1): 113-124.
16. Chi XZ, Yang JO, Lee KY, et al. RUNX3 suppresses gastric epithelial cell growth by inducing p21(WAF1/Cip1) expression in cooperation with transforming growth factor {beta}-activated SMAD. Mol Cell Biol. 2005;25(18):8097-8107.
17. Wei D, Gong W, Oh SC, et al. Loss of RUNX3 expression significantly affects the clinical outcome of gastric cancer patients and its restoration causes drastic suppression of tumor growth and metastasis. Cancer Res. 2005;65(11):4809-4816.
18. Chen LF. Tumor suppressor function of RUNX3 in breast cancer. J Cell Biochem. 2012;113(5):1470-1477.
19. Imamura Y, Hibi K, Koike M, et al. RUNX3 promoter region is specifically methylated in poorly-differentiated colorectal cancer. Anticancer Res. 2005;25(4):2627-2630.
20. Goel A, Arnold CN, Tassone P, et al. Epigenetic inactivation of RUNX3 in microsatellite unstable sporadic colon cancers. Int J Cancer. 2004;112(5):754-759.
21. Ku JL, Kang SB, Shin YK, et al. Promoter hypermethylation downregu- lates RUNX3 gene expression in colorectal cancer cell lines. Oncogene. 2004;23(40):6736-6742.
22. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM; Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics. Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst. 2005;97(16):1180-1184.
23. Steels E, Paesmans M, Berghmans T, et al. Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis. Eur Respir J. 2001;18(4):705-719.
24. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177-188.
25. Higgins J P, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557-560.
26. DerSimonian R. Meta-analysis in the design and monitoring of clinical trials. Stat Med. 1996;15(12):1237-1248; discussion 1249-1252.
27. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629-634.
28. Ahlquist T, Lind GE, Costa VL, et al. Gene methylation profiles of normal mucosa, and benign and malignant colorectal tumors identify early onset markers. Mol Cancer. 2008;7:94.
29. Soong R, Shah N, Peh BK, et al. The expression of RUNX3 in colorectal cancer is associated with disease stage and patient outcome. Br J Cancer. 2009;100(5):676-679.
30. Ito K, Lim AC, Salto-Tellez M, et al. RUNX3 attenuates beta-catenin/ T cell factors in intestinal tumorigenesis. Cancer Cell. 2008;14(3): 226-237.
31. Hibi K, Nakao A. Lymph node metastasis is infrequent in patients with highly-methylated colorectal cancer. Anticancer Res. 2006;26(1A):55-58.
32. Ogino S, Meyerhardt JA, Kawasaki T, et al. CpG island methyla- tion, response to combination chemotherapy, and patient survival in advanced microsatellite stable colorectal carcinoma. Virchows Arch. 2007;450(5):529-537.
33. Tan SH, Ida H, Lau QC, et al. Detection of promoter hypermethylation in serum samples of cancer patients by methylation-specifc polymerase chain reaction for tumour suppressor genes including RUNX3. Oncol Rep. 2007;18(5):1225-1230.
34. Silva TD, Vidigal VM, Felipe AV, et al. DNA methylation as an epigenetic biomarker in colorectal cancer. Oncol Lett. 2013;6(6):1687-1692.
35. Nishio M, Sakakura C, Nagata T, et al. RUNX3 promoter methylation in colorectal cancer: its relationship with microsatellite instability and its suitability as a novel serum tumor marker. Anticancer Res. 2010;30(7): 2673-2682.
36. Long C, Yin B, Lu Q, et al. Promoter hypermethylation of the RUNX3 gene in esophageal squamous cell carcinoma. Cancer Invest. 2007;25(8):685-690.
37. Tonomoto Y, Tachibana M, Dhar DK, et al. Differential expression of RUNX genes in human esophageal squamous cell carcinoma: downregulation of RUNX3 worsens patient prognosis. Oncology. 2007; 73(5-6):346-356.
38. Watanabe T, Kobunai T, Ikeuchi H, et al. RUNX3 copy number predicts the development of UC-associated colorectal cancer. Int J Oncol. 2011;38(1):201-207.
39. Chen W, Gao N, Shen Y, Cen JN. Hypermethylation downregulates Runx3 gene expression and its restoration suppresses gastric epithelial cell growth by inducing p27 and caspase3 in human gastric cancer. J Gastroenterol Hepatol. 2010;25(4):823-831.
40. Delpu Y, Cordelier P, Cho WC, Torrisani J. DNA methylation and cancer diagnosis. Int J Mol Sci. 2013;14(7):15029-15058.
41. Ma X, Wang Y W, Zhang MQ, Gazdar AF. DNA methylation data analysis and its application to cancer research. Epigenomics. 2013;5(3):301-316.
42. Chuang LS, Ito Y. RUNX3 is multifunctional in carcinogenesis of multiple solid tumors. Oncogene. 2010;29(18):2605-2615.
43. Jang BG, Kim WH. Molecular pathology of gastric carcinoma. Pathobiology. 2011;78(6):302-310.
44. Kohya N, Koga Y, Kitajima Y, Miyazaki K. Aberrant promoter hypermethylation in biliary tract carcinoma. J Hepatobiliary Pancreat Surg. 2006;13(4):296-305.
45. Lee JH, Pyon JK, Kim DW, et al. Expression of RUNX3 in skin cancers. Clin Exp Dermatol. 2011;36(7):769-774.
46. Lee JM, Shin JO, Cho K W, et al. Runx3 is a crucial regulator of alveolar differentiation and lung tumorigenesis in mice. Differentiation. 2011;81(4):261-268.
47. Lee YM. Control of RUNX3 by histone methyltransferases. J Cell Biochem. 2011;112(2):394-400.
48. Levanon D, Brenner O, Otto F, Groner Y. Runx3 knockouts and stomach cancer. EMBO Rep. 2003;4(6):560-564.
49. Shima K, Nosho K, Baba Y, et al. Prognostic significance of CDKN2A (p16) promoter methylation and loss of expression in 902 colorectal cancers: Cohort study and literature review. Int J Cancer. 2011;128(5): 1080-1094.
50. Tamura G. Promoter methylation status of tumor suppressor and tumor-related genes in neoplastic and non-neoplastic gastric epithelia. Histol Histopathol. 2004;19(1):221-228.
51. Tamura G. Alterations of tumor suppressor and tumor-related genes in the development and progression of gastric cancer. World J Gastroenterol. 2006;12(2):192-198.
52. Zhao C, Bu X. Promoter methylation of tumor-related genes in gastric carcinogenesis. Histol Histopathol. 2012;27(10):1271-1282.
53. Suzuki M, Shigematsu H, Shames DS, et al. DNA methylation-associated inactivation of TGFβ-related genes, DRM/Gremlin, RUNX3, and HPP1 in human cancers. Br J Cancer. 2013;109(12):3132.
54. Cassinotti E, Melson J, Liggett T, et al. DNA methylation patterns in blood of patients with colorectal cancer and adenomatous colorectal polyps. Int J Cancer. 2012;131(5):1153-1157.
55. Abouzeid HE, Kassem AM, Abdel Wahab AH, El-mezayen HA, Sharad H, Abdel Rahman S. Promoter hypermethylation of RASSF1A, MGMT, and HIC-1 genes in benign and malignant colorectal tumors. Tumour Biol. 2011;32(5):845-852.
56. Psofaki V, Kalogera C, Tzambouras N, et al. Promoter methylation status of hMLH1, MGMT, and CDKN2A/p16 in colorectal adenomas. World J Gastroenterol. 2010;16(28):3553-3560.
57. Voon DC, Wang H, Koo JK, et al. Runx3 protects gastric epithelial cells against epithelial-mesenchymal transition-induced cellular plasticity and tumorigenicity. Stem Cells. 2012;30(10):2088-2099.